X0202 SCHEDULE 13G/A 0001193125-22-292633 0001875620 XXXXXXXX LIVE 4 Common Stock, par value $0.001 per share 06/30/2026 0001781174 Acrivon Therapeutics, Inc. 004890109 480 ARSENAL WAY, SUITE 100 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 Rule 13d-1(c) Sands Capital Life Sciences Pulse Fund II, L.P. b E9 0.00 2289271.00 0.00 2289271.00 2289271.00 5.3 PN The percentages reported in this Schedule 13G are based upon 42,853,362 Shares outstanding as of August 7, 2026 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on August 12, 2026). Sands Capital Alternatives, LLC b DE 0.00 2289271.00 0.00 2289271.00 2289271.00 5.3 OO The percentages reported in this Schedule 13G are based upon 42,853,362 Shares outstanding as of August 7, 2026 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on August 12, 2026). SANDS FRANK M. b X1 0.00 2289271.00 0.00 2289271.00 2289271.00 5.3 IN HC The percentages reported in this Schedule 13G are based upon 42,853,362 Shares outstanding as of August 7, 2026 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on August 12, 2026). Acrivon Therapeutics, Inc. 480 ARSENAL WAY, SUITE 100, 480 ARSENAL WAY, SUITE 100, WATERTOWN, MASSACHUSETTS, 02472. This Schedule 13G is being filed jointly by: (i) Sands Capital Life Sciences Pulse Fund II, L.P. ("Sands Pulse Fund II"), with respect to the shares of Common Stock held by it; (ii) Sands Capital Alternatives, LLC ("Sands Capital Alternatives"), the investment manager of Sands Pulse Fund II, with respect to the shares of common Stock held by Sands Pulse Fund II; and (iii) Frank M. Sands ("Sands"), with respect to the shares of Common Stock held by Sands Pulse Fund II. Sands Pulse Fund II, Sands Capital Alternatives and Sands are together referred to herein as the "Reporting Persons". Sands Capital Life Sciences Pulse Fund II-GP, L.P. ("Sands Pulse GP LP") is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund-GP, LLC ("Sands Pulse GP LLC" and, together with Sands Pulse GP LP, the "Sands General Partners") is the general partner of Sands Pulse GP LP. Sands Capital Alternatives is the investment manager of Sands Pulse Fund II and thus may be deemed to beneficially own the shares of Common Stock held by Sands Pulse Fund II. Sands holds ultimate voting and investment power over securities held by Sands Pulse Fund II, and thus may be deemed to beneficially own the shares of Common Stock held by Sands Pulse Fund II. Each Reporting Person and the Sands General Partners disclaim beneficial ownership of any securities beyond its pecuniary interest therein. The principal business address of each of the Reporting Persons and the Sands General Partners is 1000 Wilson Blvd., Suite 3000, Arlington, VA 22209. Sands Pulse Fund II and Sands Pulse GP LP are organized under the laws of the Cayman Islands. Sands Capital Alternatives and Sands Pulse GP LLC are organized under the laws of Delaware. Sands is a citizen of the United States. Y See rows 5 through 11 of cover pages. See rows 5 through 11 of cover pages. See rows 5 through 11 of cover pages. See rows 5 through 11 of cover pages. See rows 5 through 11 of cover pages. See rows 5 through 11 of cover pages. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Sands Capital Life Sciences Pulse Fund II, L.P. /s/ Jonathan Goodman 08/13/2026 Sands Capital Alternatives, LLC /s/ Jonathan Goodman 08/13/2026 SANDS FRANK M. /s/ Frank M. Sands 08/13/2026 Sands Capital Life Sciences Pulse Fund II, L.P. signed by Sands Capital Life Sciences Pulse Fund II-GP, L.P., its general partner, by Sands Capital Life Sciences Pulse Fund II-GP, LLC, its general partner, by Jonathan Goodman, General Counsel.